New facility serves biopharma manufacturers throughout the region with local access to customer purification studies across Ecolab's Purolite™ Resin portfolio
SEOUL, Korea. – Apr. 29, 2026 - Ecolab Life Sciences is expanding the bioprocessing business with the launch of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, giving biopharmaceutical manufacturers across Asia local better access to downstream process development support. Strategically located to serve customers throughout the region, the site is Ecolab's first bioprocessing facility in Asia and joins an established applications network in the United States and the United Kingdom.
BPAL Korea supports process development from early-stage resin screening through studies designed to replicate commercial manufacturing conditions. On-site scientists work alongside customers across Asia to help optimize chromatography steps, improve yield and productivity, and accelerate regulatory pathways, reducing the need to ship resins and reference materials overseas for development work.
Asia has become one of the world's most active biopharmaceutical manufacturing regions, with Korea, China, Japan, India, and Singapore all home to growing pipelines in biosimilars and monoclonal antibody processes that demand efficient, scalable downstream purification. With local technical support now in place, manufacturers across the region can shorten development cycles and maintain consistency with global operations while working to tight regulatory and cost targets.
"Biopharmaceutical manufacturers across Asia are under increasing pressure to scale with speed while meeting demanding regulatory and performance expectations," said Jenny Tan, vice president and general manager, Ecolab Life Sciences APAC and India. "BPAL Korea strengthens our ability to work side by side with customers, bringing deep local expertise together with Ecolab's global, integrated bioprocessing network."
By combining local scientific support with Ecolab’s innovative Purolite™ resin portfolio, Ecolab’s new BPAL helps enables manufacturers to address process challenges earlier, reduce development risk, and advance programmes with greater confidence as they prepare for scale‑up.
To learn more about Ecolab Life Sciences' bioprocessing development capabilities and how BPAL Korea supports scalable, regulatory-ready purification processes for customers across Asia click
here
